Breaking News

Evonik Invests €25M to Increase Manufacture of APIs in Germany

To expand Dossenheim and Hanau sites to increase EU supply security for drug products.

By: Contract Pharma

Contract Pharma Staff

Evonik is investing €25 million in the first stage of a long-term program to expand the capacity at its Dossenheim and Hanau facilities in Germany to support contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates within Europe. The first stage of the expansion project is scheduled to be completed by mid-2021, with the entire project expected to be finalized prior to 2024. “The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters